Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520713 | 0.94 | MAPT (0.50) | ALDH1A1MLYCDHTR7MAPTKDM4E | |
| SCHEMBL519767 | 0.88 | HTR7 (0.53) | MLYCDHTR7MAPTKDM4EMEN1 | |
| SCHEMBL520529 | 0.87 | ADRA2C (0.57) | ALDH1A1MLYCDMAPTKDM4ELMNA | |
| SCHEMBL519800 | 0.85 | ALDH1A1 (0.41) | ALDH1A1MLYCDHTR7KDM4EENPP2 | |
| SCHEMBL2481413 | 0.85 | ALDH1A1 (0.41) | ALDH1A1MLYCDHTR7KDM4EENPP2 | |
| SCHEMBL1811762 | 0.79 | SIRT6 (0.59) | ALDH1A1MAPTLMNARAB9ASMN1; SMN2 | |
| SCHEMBL1126076 | 0.78 | MAPT (0.60) | ALDH1A1HTR7MAPTKDM4EMEN1 | |
| SCHEMBL2658444 | 0.76 | POLB (0.52) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL31232720 | 0.75 | HTR7 (0.56) | HTR7MAPTKDM4EMEN1KMT2A | |
| SCHEMBL520396 | 0.75 | HTR7 (0.56) | ALDH1A1HTR7MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | ALDH1A1 779/4885MLYCD 3386/4885HTR7 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.